Evidence map›Paper›PMID 26668022›Full record

Observational studyClinical journal of the American Society of Nephrology : CJASN2016

Predictors of Subclinical Atheromatosis Progression over 2 Years in Patients with Different Stages of CKD.

Marta Gracia, Àngels Betriu, Montserrat Martínez-Alonso, David Arroyo, María Abajo, Elvira Fernández, José M Valdivielso, NEFRONA Investigators

Open access · greenAbstract readComparative StudyMulticenter StudyObservational Study
In one paragraph

Observational study in Clinical journal of the American Society of Nephrology : CJASN, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 2 pooled it
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 83 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Marta GraciaExperimental Nephrology, Biomedical Research Institute of Lleida (IRBLleida), Lleida, Spain;
Àngels BetriuExperimental Nephrology, Biomedical Research Institute of Lleida (IRBLleida), Lleida, Spain;
Montserrat Martínez-AlonsoBiostatistics, IRBLleida, Lleida, Spain; and.
David ArroyoNephrology, University Hospital Arnau de Vilanova, Lleida, Spain.
María AbajoExperimental Nephrology, Biomedical Research Institute of Lleida (IRBLleida), Lleida, Spain;
Elvira FernándezBiostatistics, IRBLleida, Lleida, Spain; and.
José M ValdivielsoExperimental Nephrology, Biomedical Research Institute of Lleida (IRBLleida), Lleida, Spain; edfernandez.lleida.ics@gencat.cat valdivielso@medicina.udl.cat.
NEFRONA Investigators
Biomedical Research Institute of Lleida · ESHospital Universitari Arnau de Vilanova · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesUltrasonographic detection of subclinical atheromatosis is a noninvasive method predicting cardiovascular events. Risk factors predicting atheromatosis progression in CKD are unknown. Predictors of atheromatosis progression were evaluated in patients with CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Our multicenter, prospective, observational study included 1553 patients with CKD (2009-2011). Carotid and femoral ultrasounds were performed at baseline and after 24 months. A subgroup of 476 patients with CKD was also randomized to undergo ultrasound examination at 12 months. Progression of atheromatosis was defined as an increase in the number of plaque territories analyzed by multivariate logistic regression.

resultsPrevalence of atheromatosis was 68.7% and progressed in 59.8% of patients after 24 months. CKD progression was associated with atheromatosis progression, suggesting a close association between pathologies. Variables significantly predicting atheromatosis progression, independent from CKD stages, were diabetes and two interactions of age with ferritin and plaque at baseline. Given that multiple interactions were found between CKD stage and age, phosphate, smoking, dyslipidemia, body mass index, systolic BP (SBP), carotid intima-media thickness, plaque at baseline, uric acid, cholesterol, 25-hydroxy vitamin D (25OH vitamin D), and antiplatelet and phosphate binders use, the analysis was stratified by CKD stages. In stage 3, two interactions (age with phosphate and plaque at baseline) were found, and smoking, diabetes, SBP, low levels of 25OH vitamin D, and no treatment with phosphate binders were positively associated with atheromatosis progression. In stages 4 and 5, three interactions (age with ferritin and plaque and plaque with smoking) were found, and SBP was positively associated with atheromatosis progression. In dialysis, an interaction between body mass index and 25OH vitamin D was found, and age, dyslipidemia, carotid intima-media thickness, low cholesterol, ferritin, and uric acid were positively associated with atheromatosis progression.

conclusionsAtheromatosis progression affects more than one half of patients with CKD, and predictive factors differ depending on CKD stage.

Indexed as

Carotid Artery, CommonPlaque, AtheroscleroticAdultAgedAsymptomatic DiseasesAtherosclerosisCarotid Artery DiseasesCarotid Intima-Media ThicknessChi-Square DistributionComorbidityDisease ProgressionFemaleFemoral ArteryHumansLife StyleLogistic Modelsatherosclerosisblood pressurecardiovascular diseasecarotid intima-media thicknesschronic kidney diseasefollow-up studieshumansrenal insufficiency, chronicsmokingvitamin D

Identifiers

PMID26668022
PMCPMC4741032
OpenAlexW2198396599

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.